Table 3 Treatment information and outcomes of the included studies
Authors | Year | SBRT dose, fractionation scheme | BED10, Gy median (range) | 1-year OS | 3-year OS | 1-year LC | 3-year LC | Grade ≧ 3 hepatic complication (%) | RILD (%) | Follow-up, months |
|---|---|---|---|---|---|---|---|---|---|---|
Sun et al. [10] | 2019 | 48–54 Gy/5-8F | 100 (76.8–102.6) | 96.3% | 80.6% | 98.1% | 95.1% | 0/108(0%) | 8/108(7.4%) | 42 (6–77) |
Parikh et al. [11] | 2018 | NR | NR | 78.1% | – | – | – | – | – | 16.2 (IQR: 13.4–26.9) |
Jun et al. [22] | 2018 | 40–60 Gy/3-5F | (72–180) | – | – | 91.1% | 89.9% | – | – | NR |
Jeong et al. [19] | 2018 | 30–60 Gy/3-4F | 104.06 (60–180) | 99.2% | 83.8% | 98.5% | 97.0% | 4/119 (3.4%) | 10/119(8.4%) | 25.8 (3.2–36.8) |
Su et al. [23] | 2016 | 42–46 Gy/3–5F 28–30 Gy/1F | (77.3–162.5) | 94.1% | 73.5% | 90.9% | – | 6/132 (4.5%) | – | 21.0 (3–76) |
Scorsetti et al. [8] | 2015 | 48–75 Gy/3F 36–60 Gy/6F | (57.6–262.5) | 77.9% | – | 85.8% | – | 7/43 (16.3%) | – | 8 (3–43) |
Kimura et al. [24] | 2015 | 48 Gy/4F | 105.6 | 92.0% | – | 100% | – | – | – | 26 |
Shiozawa et al. [12] | 2015 | NR | NR | 95.2% | – | 97.1% | – | – | – | 12.6 |
Sanuki et al. [25] | 2014 | 35 or 40 Gy/5F | 72 (59.5 or 72) | 95.0% | 70.0% | 99.0% | 91.0% | – | – | 24 (3–80) |
Yoon et al. [9] | 2013 | 30–60 Gy/3-4F | 104.06 (60–180) | 86.0% | 53.8% | 94.8% | 92.1% | – | – | 25.6 (1.8–55.4) |
Kwon et al. [16] | 2010 | 30–39 Gy/3F | (60–89.7) | 92.9% | 58.6% | 72.0% | 68.0% | – | – | 28.7 (8.4–49.1) |
Jun et al. [17] | 2018 | 40–60 Gy/3-5F | (72–180) | – | – | – | – | – | 29/117 (24.7%) | 22.5 (3–56)-after SBRT |
Takeda et al. [26] | 2016 | 35 or 40 Gy/5F | (59.5 or 72) | – | – | – | – | 2/90 (2.2%) | – | 41.7 (6.8–96.2) |
Jung et al. [18] | 2013 | 30–60 Gy/3-4F | (60–150) | – | – | – | – | 6/92 (6.5%) | 17/92 (18.4%) | 25.7 (1.8–55.4) |